Thomas John
A5089757931- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Occupational and environmental lung diseases
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Pleural and Pulmonary Diseases
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Genetic factors in colorectal cancer
- Ocular Surface and Contact Lens
- Medical Imaging and Pathology Studies
- Melanoma and MAPK Pathways
- Immune Cell Function and Interaction
- Blood properties and coagulation
- Cancer therapeutics and mechanisms
- CAR-T cell therapy research
Peter MacCallum Cancer Centre
2019-2025
The University of Melbourne
2016-2025
University of Toronto
2009-2025
Edinburgh Cancer Research
2013-2025
Ontario Institute for Cancer Research
2010-2025
Saarland University
2022-2025
Austin Health
2015-2024
Austin Hospital
2009-2024
Olivia Newton-John Cancer Wellness & Research Centre
2014-2023
Merck (Germany)
2023
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients mutation–positive advanced non–small-cell lung cancer (NSCLC). The showed longer progression-free survival than comparator (hazard ratio for disease progression or death, 0.46). Data from final...
Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment the proportion cells staining for nuclear antigen Ki67 has become most widely used method comparing between tumor samples. Potential uses include prognosis, prediction relative responsiveness or resistance to chemotherapy endocrine therapy, estimation residual risk in patients on standard therapy and as dynamic biomarker treatment efficacy samples taken before, during, after neoadjuvant...
Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant are unknown.
Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety osimertinib (an epidermal growth factor receptor [EGFR] –tyrosine kinase inhibitor selective for EGFR–tyrosine sensitizing [ EGFRm] EGFR T790M resistance mutations) as first-line treatment EGFR-mutated advanced non–small-cell lung cancer (NSCLC). Patients Methods Sixty with locally or metastatic EGFRm NSCLC received 80 160 mg once daily...
Among patients with resected, epidermal growth factor receptor (EGFR)-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, or without previous chemotherapy, resulted in significantly longer disease-free survival than placebo the ADAURA trial. We report results of planned final analysis overall survival.In this phase 3, double-blind trial, we randomly assigned eligible a 1:1 ratio receive (80 mg once daily) until disease recurrence was observed, trial...
The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30];
•Median OS with osimertinib was 26.8 months versus 22.5 platinum–pemetrexed (HR 0.87, 95% CI 0.67–1.12; P = 0.277).•The lack of a significant survival benefit could reflect high percentage (73%) to crossover.•Analysis adjusted for crossover showed an HR 0.54 (95% 0.18–1.60).•Among patients receiving subsequent anticancer therapy, platinum chemotherapy the most common after (65%).•Grade ≥3 (possibly treatment-related) adverse events were observed less frequently (9% 34% platinum–pemetrexed)....
Abstract Malignant melanoma is one of the most difficult cancers to treat due its resistance chemotherapy. Despite recent successes with BRAF inhibitors and immune checkpoint inhibitors, many patients do not respond or become resistant these drugs. Hence, alternative treatments are still required. Due importance BCL-2-regulated apoptosis pathway in cancer development drug resistance, it interest establish which proteins important for cell survival, though outcomes previous studies have been...
Abstract Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the research communities. We evaluated sources of variability sTIL assessment pathologists three previous ring studies. identify common challenges evaluate impact...
To further characterize survival benefit with first-line nivolumab plus ipilimumab two cycles of chemotherapy versus alone, we report updated data from the phase III CheckMate 9LA trial a 2-year minimum follow-up.
9501 Background: NIVO + IPI was shown to improve overall survival (OS) and durability of response vs chemo in 1L advanced NSCLC CheckMate 227 Part 1, regardless PD-L1 expression. We hypothesized that a limited course combined with could provide rapid disease control while building on the durable OS benefit seen dual PD-1 CTLA-4 inhibition. 9LA (NCT03215706) is phase 3 randomized study evaluating 2 cycles stage IV/recurrent NSCLC. Methods: Adults tx-naive, histologically confirmed NSCLC, ECOG...
Abstract Purpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, previously induced deep [objective response rate (ORR) 57.4%] durable [median duration of (DoR) 10.4 months] responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This article expands prior reports additional patients longer follow-up. Patients Methods: locally advanced/metastatic ≥12 months' follow-up were included. Primary endpoints ORR DoR by blinded...
Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found have a clinically meaningful improvement disease-free survival (DFS) IB EGFR-mutated (EGFRm) NSCLC. Here, we report prespecified and exploratory analyses of adjuvant use outcomes from ADAURA.Patients EGFRm NSCLC were randomized 1:1 receive or placebo for years. before randomization not...
Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to epidermal growth factor receptor 3 (HER3) attached topoisomerase I inhibitor payload via stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety HER3-DXd in patients with (